Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report2026
2. 2Dynamic Therapeutic Response to Osimertinib and Immunotherapy in an EGFR L747S and L858R co-mutant NSCLC2026
3. 3EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report2024 · 1 citations
4. 4Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions2026
5. 5Stage 4A Lung Adenocarcinoma with Rare EGFR Exon 21 L861Q and Exon 18 G719A Co-Mutations Showing Complete PET-CT Response to Osimertinib: A Case Report2026